26 April 2013
ADVANCED ONCOTHERAPY Plc
("Advanced Oncotherapy" or "the Company")
Director Appointment
Further to the Issue of Equity announcement released on 24 April 2013, Advanced Oncotherapy is pleased to announce the appointment of Michael Bradfield as a Non-Executive director of the Company. This appointment follows Mr Bradfield's £1m investment in the Company ("the Placing").
Michael Bradfield, aged 61, has over 30 years experience of Direct Marketing and the Insurance Industry as founder and CEO of Hospital Plan Insurance Services (HPIS), a direct seller of low cost Health, Accident and Life Insurance. Michael has a law degree from LSE, was the youngest full Member of Lloyds of London and a computer application programmer since the late 1960's, specialising in insurance based administration and correspondence systems and database marketing. HPIS was sold to AIG in 2000 when it expanded into Europe. Since 2004 he has been an active investment manager, especially in technology based companies and sustainable industries.
Current Directorships |
Past Directorships |
Stockgain Asset Management |
The Heriot Property Partnership LLP |
Henstridge Properties Limited |
Twizzle Yachts Limited Liability Partnership |
The Vail Foundation |
Data For Marketing Limited |
Hamilton Capital Management Limited |
Acacia Trust |
Fairford Capital Limited |
Acacia Asset Management Limited |
|
Acacia Research Limited |
There is no further information required to be disclosed under paragraph (g) of Schedule 2 of the AIM Rules.
Following the admission of the Placing shares, Mr. Bradfield will hold 100,000,000 ordinary shares, representing approximately 27.8 per cent. of the issued share capital of Advanced Oncotherapy.
Commenting on the appointment, Michael Sinclair, Chief Executive said "I am delighted to welcome Michael to our board. His experience will undoubtedly help us to grow the company and he has already demonstrated his enthusiasm through the substantial investment he has made in Advanced Oncotherapy."
For further information, please visit www.advancedoncotherapy.comor contact:
Michael Sinclair, Chief Executive |
Sandy Jamieson |
Jon Levinson |
Simon Hudson |
Advanced Oncotherapy Plc |
Libertas Capital Corporate Finance Ltd |
Peterhouse Corporate Finance |
Tavistock Communications |
|
(NOMAD & Joint Broker) |
(Joint Broker) |
(Financial PR & IR) |
+44 20 3617 8739 |
+44 20 7569 9650 |
+44 20 7469 0930 |
+44 20 7920 3150 |